Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoy, Amitesh C-
dc.contributor.authorShapiro, Jeremy-
dc.contributor.authorBurge, Matt-
dc.contributor.authorKarapetis, Christos S-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorSegelov, Eva-
dc.contributor.authorChau, Ian-
dc.contributor.authorLordick, Florian-
dc.contributor.authorChen, Li-Tong-
dc.contributor.authorBarbour, Andrew-
dc.contributor.authorTebbutt, Niall-
dc.contributor.authorPrice, Tim-
dc.identifier.citationExpert review of anticancer therapy 2020; online first: 21 March-
dc.description.abstractIntroduction: A multimodal approach in operable early stage oesophago-gastric (OG) cancer has evolved in the last decade, leading to improvement in overall outcomes.Areas covered: A review of the published literature and conference abstracts was undertaken on the topic of optimal adjunctive chemotherapy or chemoradiotherapy in early stage OG cancers. This review article focuses on the current evidence pertaining to neo-adjuvant and perioperative strategies in curable OG cancers including the evolving landscape of immunotherapy and targeted drugs in this setting.Expert commentary: Adjunctive therapies in the form of pre-operative chemo-radiotherapy (CRT) or chemotherapy and perioperative chemotherapy over surgery alone improves outcomes in patients with operable OG cancer. Although there are variations in practice around the world, a multi-disciplinary approach to patient care is of paramount importance. Immunotherapy and on treatment functional imaging are two examples of emerging strategies to improve outcome for early stage patients. Better understanding of the molecular biology of this disease may help overcome the problem of tumour heterogeneity and enable more rationally designed and targeted therapeutic interventions in the future.-
dc.titleManagement of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.-
dc.typeJournal Article-
dc.identifier.journaltitleExpert review of anticancer therapy-
dc.identifier.affiliationCabrini Health, Monash University, Melbourne, Australiaen
dc.identifier.affiliationQueen Elizabeth Hospital/University of Adelaide, Adelaide, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationThe University of Queensland Diamantina Institute, the University of Queensland, Woolloongabba, QLD, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Monash University and Monash Health, Melbourne 3800, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Royal North Shore Hospital, Sydney 2065, Australiaen
dc.identifier.affiliationFlinders Centre For Innovation in Cancer/Flinders University, Bedford Park, South Australia, 5042, Australiaen
dc.identifier.affiliationDepartment of Cancer Care Services, Royal Brisbane Hospital, University Of Queensland, Herston, Queensland..-
dc.identifier.affiliationDept. of Medical Oncology, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, UK, SM2 5PT..-
dc.identifier.affiliationUniversity Cancer Centre Leipzig, Leipzig University Medical Centre, Leipzig, Germany..-
dc.identifier.affiliationNational Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan..-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.